Key Points The bull case wasn't helped by an analyst's recommendation downgrade. That pundit now feels the biotech's shares only rate a hold. 10 stocks we like better than Madrigal Pharmaceuticals › The New Year's Champagne turned flat for Madrigal Pharmaceuticals (NASDAQ: MDGL) on Tuesday. Investors traded out of the commercial-stage biotech following an analyst's recommendation downgrade. This resulted in the stock's price eroding by more than 5% that trading session. A high bar The prognostic ...